|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/19 Nymox Pharmaceutical Corp 20-F 12/31/18 107:5.1M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual Report by a Foreign Non-Canadian Issuer HTML 837K
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 24K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 25K
2: EX-12.A Statement re: Computation of Ratios HTML 30K
3: EX-12.B Statement re: Computation of Ratios HTML 30K
12: R1 Document and Entity Information HTML 58K
13: R2 Consolidated Statements of Financial Position HTML 86K
14: R3 Consolidated Statements of Financial Position HTML 27K
(Parenthetical)
15: R4 Consolidated Statements of Comprehensive Income HTML 76K
16: R5 Consolidated Statements of Changes in Equity HTML 69K
17: R6 Consolidated Statements of Cash Flow HTML 90K
18: R7 Business Activities and Basis of Presentation HTML 36K
19: R8 Going Concern Considerations HTML 29K
20: R9 Significant Estimates HTML 27K
21: R10 Significant Accounting Policies HTML 70K
22: R11 New Accounting Standards and Interpretations HTML 38K
23: R12 Property and Equipment HTML 88K
24: R13 Intangible Assets HTML 28K
25: R14 Accounts Payable and Accrued Liabilities HTML 38K
26: R15 Convertible Notes HTML 39K
27: R16 Commitments and Contingencies HTML 44K
28: R17 Share Capital HTML 40K
29: R18 Stock Options HTML 50K
30: R19 Share Based Compensation HTML 36K
31: R20 Warrants HTML 58K
32: R21 Income Taxes HTML 75K
33: R22 Earnings Per Share HTML 34K
34: R23 Financial Instruments Fair Value Disclosures HTML 28K
35: R24 Finance Income and Finance Costs HTML 48K
36: R25 Segment Disclosures HTML 43K
37: R26 Concentrations HTML 31K
38: R27 Related Party Transactions HTML 39K
39: R28 Research and Development Expenses HTML 39K
40: R29 Personnel Expenses HTML 36K
41: R30 Capital Disclosures and Financial Risk HTML 29K
42: R31 Foreign Exchange Risk HTML 28K
43: R32 Credit Risk HTML 30K
44: R33 27. Interest Rate Risk HTML 27K
45: R34 28. Liquidity Risk HTML 40K
46: R35 29. Subsequent Events HTML 28K
47: R36 Significant Accounting Policies (Policies) HTML 121K
48: R37 Significant Accounting Policies (Tables) HTML 29K
49: R38 Property and Equipment (Tables) HTML 87K
50: R39 Accounts Payable and Accrued Liabilities (Tables) HTML 36K
51: R40 Convertible Notes (Tables) HTML 35K
52: R41 Commitments and Contingencies (Tables) HTML 43K
53: R42 Share Capital (Tables) HTML 36K
54: R43 Stock Options (Tables) HTML 55K
55: R44 Share Based Compensation (Tables) HTML 33K
56: R45 Warrants (Tables) HTML 55K
57: R46 Income Taxes (Tables) HTML 74K
58: R47 Earnings Per Share (Tables) HTML 33K
59: R48 Finance Income and Finance Costs (Tables) HTML 47K
60: R49 Segment Disclosures (Tables) HTML 42K
61: R50 Concentrations (Tables) HTML 31K
62: R51 Related Party Transactions (Tables) HTML 35K
63: R52 Research and Development Expenses (Tables) HTML 38K
64: R53 Personnel Expenses (Tables) HTML 36K
65: R54 Liquidity risk (Tables) HTML 38K
66: R55 Significant Accounting Policies (Details) HTML 33K
67: R56 Property and Equipment (Details) HTML 61K
68: R57 Property and Equipment (Details Narrative) HTML 28K
69: R58 Intangible Assets (Details Narrative) HTML 37K
70: R59 Accounts Payable and Accrued Liabilities (Details) HTML 33K
71: R60 Convertible Notes (Details) HTML 31K
72: R61 Convertible Notes (Details Narrative) HTML 39K
73: R62 Commitments and Contingencies (Details) HTML 36K
74: R63 Commitments and Contingencies (Details 1) HTML 33K
75: R64 Commitments and Contingencies (Details 2) HTML 35K
76: R65 Commitments and Contingencies (Details Narrative) HTML 38K
77: R66 Share Capital (Details) HTML 29K
78: R67 Share Capital (Details Narrative) HTML 38K
79: R68 Stock Options (Details) HTML 50K
80: R69 Stock Options (Details 1) HTML 43K
81: R70 Stock Options (Details Narrative) HTML 29K
82: R71 Share Based Compensation (Details) HTML 34K
83: R72 Share Based Compensation (Details Narrative) HTML 37K
84: R73 Warrants (Details) HTML 45K
85: R74 Warrants (Details Narrative) HTML 35K
86: R75 Income Taxes (Details) HTML 44K
87: R76 Income Taxes (Details 1) HTML 32K
88: R77 Income Taxes (Details 2) HTML 83K
89: R78 Income Taxes (Details Narrative) HTML 28K
90: R79 Earnings Per Share (Details) HTML 31K
91: R80 Financial Instruments Fair Value Disclosures HTML 26K
(Details Narrative)
92: R81 Finance Income and Finance Costs (Details) HTML 46K
93: R82 Segment Disclosures (Details) HTML 43K
94: R83 Concentrations (Details) HTML 32K
95: R84 Related Party Transactions (Details) HTML 37K
96: R85 Related Party Transactions (Details Narrative) HTML 36K
97: R86 Research and Development Expenses (Details) HTML 40K
98: R87 Personnel Expenses (Details) HTML 36K
99: R88 Capital Disclosures and Financial Risk (Details HTML 41K
Narrative)
100: R89 Foreign Exchange risk (Details Narrative) HTML 27K
101: R90 Credit risk (Details Narrative) HTML 33K
102: R91 Interest rate risk (Details Narrative) HTML 26K
103: R92 Liquidity risk (Details) HTML 37K
104: R93 Subsequent Events (Details Narrative) HTML 39K
106: XML IDEA XML File -- Filing Summary XML 195K
105: EXCEL IDEA Workbook of Financial Reports XLSX 100K
6: EX-101.INS XBRL Instance -- nymx-20181231 XML 1.72M
8: EX-101.CAL XBRL Calculations -- nymx-20181231_cal XML 142K
9: EX-101.DEF XBRL Definitions -- nymx-20181231_def XML 469K
10: EX-101.LAB XBRL Labels -- nymx-20181231_lab XML 895K
11: EX-101.PRE XBRL Presentations -- nymx-20181231_pre XML 742K
7: EX-101.SCH XBRL Schema -- nymx-20181231 XSD 294K
107: ZIP XBRL Zipped Folder -- 0001640334-19-000464-xbrl Zip 132K
EXHIBIT 12 (a)
CERTIFICATION
I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that:
| 1. | I have reviewed this annual report for the period ended December 31, 2018 of Nymox Pharmaceutical Corporation; |
|
| |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
| |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
|
| |
|
4. | The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a–15(f) and 15d–15(f)) for the company based on the COSO 1992 framework and we have: |
|
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards; |
|
| c) | evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
| d) | disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and |
| 5. | The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent function): |
|
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
|
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
| Date: March 29, 2019 | ||
|
| ||
| By: | ||
|
| ||
|
| President and Chief Executive Officer | |
|
| Nymox Pharmaceutical Corporation | |
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/29/19 | None on these Dates | ||
| For Period end: | 12/31/18 | |||
| List all Filings | ||||